Original Source(s)
Related Content
FDA Investigates Malignancy Risk Linked to Zolgensma Gene Therapy
Vector DNA integration was identified near or within the GLI1 oncogene in tumors from two treated patients
November 11, 2026
-
3 min
FDA Updates Potency Rules for Cell and Gene Therapies
Replacing guidance from 2011, the FDA's updated framework emphasizes potency assurance throughout cell and gene therapy development and manufacturing
November 11, 2026
-
3 min
